← Back to Search

Anticoagulant

Tinzaparin for Kidney Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by University of Vermont

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No signs or symptoms of bleeding within the past 4 weeks

No uncontrolled severe intercurrent illness, including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will give tinzaparin to patients with metastatic kidney cancer to see if it can help.

Who is the study for?

This trial is for adults with metastatic kidney cancer that can't be surgically removed. They should have a certain type of cancer cell (clear cell histology), no brain metastases, and their major organs must function well. They need to survive more than 2 months, not be pregnant or nursing, and use effective contraception.Check my eligibility

What is being tested?

The trial is testing Tinzaparin's effectiveness in stopping the growth of kidney cancer by blocking blood flow to the tumor. It's a phase I/II study which means they're looking at how safe it is and how well it works.See study design

What are the potential side effects?

Potential side effects may include bleeding risks due to Tinzaparin’s blood-thinning properties, allergic reactions if sensitive to heparin or related substances, and possibly injection site discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I haven't had any bleeding in the last month.

Select...

I don't have any severe illnesses or conditions that are not under control.

Select...

I can care for myself and am up and about more than 50% of my waking hours.

Select...

My kidney cancer is confirmed to be of a specific type under the microscope.

Select...

I don't have blood clots that need blood thinners during the study.

Select...

My cancer has spread beyond the regional lymph nodes and cannot be surgically removed.

Select...

I can receive shots under my skin at home.

Select...

I haven't had significant bleeding or conditions that increase my risk of bleeding recently.

Select...

I do not have diabetic eye problems or a history of bleeding in the eye.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood markers or coagulation as measured by plasma prothrombin F1.2, thrombin-antithrombin complexes, and D-dimers at 2 weeks, 2 months and 6 months

Secondary outcome measures

Blood markers of angiogenesis as measured by serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) at 2 weeks, 2 months, and 6 months

Progression free survival as measured by clinical evaluation at 4 months

Venous thromboembolism as measured by clinical evaluation at 6 months

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of VermontLead Sponsor

266 Previous Clinical Trials

3,743,656 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,118 Total Patients Enrolled

Deborah L. Ornstein, MDStudy ChairYale University

Media Library

Tinzaparin (Anticoagulant) Clinical Trial Eligibility Overview. Trial Name: NCT00293501 — Phase 1 & 2

Kidney Cancer Clinical Trial 2023: Tinzaparin Highlights & Side Effects. Trial Name: NCT00293501 — Phase 1 & 2

Tinzaparin (Anticoagulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00293501 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment still open to accepting new participants?

"Per clinicaltrials.gov, this particular medical trial is not currently taking on any new participants. It was initially posted in December of 2005 and revised 8 years later in November of 2013; however, there are 423 alternative trials recruiting right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

2005. "Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00293501.

All > Kidney Cancer